GENOR BIOPHARMA DL-00002 (67N0) — Working Capital to Net Assets Ratio
GENOR BIOPHARMA DL-00002 (67N0) has a Working Capital to Net Assets ratio of 75.2% as of June 2025. Working capital of €826.55 Million (current assets of €1.04 Billion minus current liabilities of €210.55 Million) is measured against net assets of €1.10 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See GENOR BIOPHARMA DL-00002 (67N0) net asset quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
GENOR BIOPHARMA DL-00002 Working Capital to Net Assets (2021–2024)
This chart shows how GENOR BIOPHARMA DL-00002's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of June 2025, the ratio stands at 75.2%, reflecting working capital of €826.55 Million against net assets of €1.10 Billion EUR. Check GENOR BIOPHARMA DL-00002 tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for GENOR BIOPHARMA DL-00002 (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for GENOR BIOPHARMA DL-00002 from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 67N0 stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 82.1% | €945.21 Million | €1.15 Billion | €1.07 Billion | €122.09 Million | ▼ -2.9 pp |
| 2023 | 85.0% | €1.01 Billion | €1.19 Billion | €1.24 Billion | €229.53 Million | ▲ +4.1 pp |
| 2022 | 80.9% | €1.46 Billion | €1.81 Billion | €1.72 Billion | €260.39 Million | ▼ -2.3 pp |
| 2021 | 83.2% | €2.07 Billion | €2.49 Billion | €2.39 Billion | €313.19 Million | — |